caption stringlengths 0 3.92k | molecule stringlengths 1 914 | properties listlengths 1 113 | additional_data dict |
|---|---|---|---|
The molecule is a nutrient, membrane stabilizer, fat storage that impacts pancreatitis, metabolic syndrome, and cardiovascular disease. The molecule is a energy storage and inflammatory, and it impacts atherosclerosis. The molecule is a energy source that impacts thyroxine treatment, cancer, and obesity. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)CC | [
"nutrient",
"Pancreatitis",
"Metabolic syndrome",
"Membrane stabilizer",
"Cardiovascular disease",
"Fat storage",
"Atherosclerosis",
"Energy storage",
"inflammatory",
"Thyroxine treatment",
"Cancer",
"Energy source",
"Obesity"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a anti tumour and a anti proliferative. | O=C([O-])C1CC(OS(=O)(=O)c2ccc([N+](=O)[O-])cc2)CN1C(=O)[O-] | [
"anti tumour",
"anti proliferative"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on stomach cancer, and impacts diabetes mellitus, colorectal cancer, and parkinson's disease. It impacts alzheimer's disease, cardiovascular disease, seizure, and breast cancer. | CCCCCC/C=C\CCCCCCCCCC(=O)OC[C@@H]1COP(=O)(O)O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](C/C=C\CC(=O)O1)[C@@H](O)C[C@@H](O)[C@H](/C=C\[C@H](O)CCCCC)[C@@H](O)[C@H]2O | [
"Diabetes mellitus",
"Stomach cancer",
"Colorectal cancer",
"Parkinson's disease",
"Alzheimer's Disease",
"Cardiovascular disease",
"Seizure",
"Breast cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, membrane stabilizer, fat storage that belongs to the thyroxine treatment class of molecules and impacts both atherosclerosis and cardiovascular disease. The molecule is a energy storage that impacts both cancer and pancreatitis. The molecule is a inflammatory and a energy source, impacting b... | CCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"nutrient",
"Thyroxine treatment",
"Membrane stabilizer",
"Atherosclerosis",
"Fat storage",
"Cardiovascular disease",
"Cancer",
"Energy storage",
"Pancreatitis",
"inflammatory",
"Metabolic syndrome",
"Energy source",
"Obesity"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both metabolic syndrome and pancreatitis. The molecule is a fat storage and belongs to the thyroxine treatment class of molecules, impacting both atherosclerosis and cardiovascular disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCC/C=C\C/C=C\C/C=C\CCCCC | [
"Metabolic syndrome",
"nutrient",
"Pancreatitis",
"Atherosclerosis",
"Fat storage",
"Cardiovascular disease",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts aging and tangier disease. The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, diabetic heart disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Aging",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Cholesterol translocation",
"Barth syndrome",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a kinase inhibitor, a protein kinase inhibitor, and a cmet inhibitor, belonging to the anti cancer agent class of molecules and is anti cancer. | O=C(NCCN1CCOCC1)Nc1nc2ccc(OS(=O)(=O)c3c(Cl)cccc3Cl)cc2[nH]1 | [
"anti cancer agent",
"kinase inhibitor",
"protein kinase inhibitor",
"cmet inhibitor",
"anti cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a pain treatment. | CN(CCNC(=O)C#Cc1cccc(Cl)c1)c1nccs1 | [
"pain treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts tangier disease, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts barth syndrome and aging. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Tangier disease",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Barth syndrome",
"Aging",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a membrane stabilizer, impacting both barth syndrome and aging. The molecule is a emulsifier, apoptosis, surfactant, food additive that impacts diabetic heart disease. The molecule is a energy source, a energy storage, a stabilizing cytochrome oxidase, and... | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Aging",
"Membrane stabilizer",
"Emulsifier",
"Apoptosis",
"surfactant",
"Diabetic heart disease",
"food additive",
"Energy source",
"Smooth",
"Energy storage",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a thyroxine treatment and fat storage, and it impacts pancreatitis. The molecule is a nutrient that impacts cardiovascular disease, atherosclerosis, and metabolic syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCC/C=C\C/C=C\C/C=C\CCCCC)COC(=O)CCCCCCCCCCCCCC | [
"Thyroxine treatment",
"Fat storage",
"Pancreatitis",
"Cardiovascular disease",
"Atherosclerosis",
"Metabolic syndrome",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts barth syndrome and tangier disease. The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts aging, diabetic heart disease, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Cholesterol translocation",
"Aging",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@H](N)C(=O)O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, inflammatory, energy storage, membrane stabilizer that has an effect on cancer and impacts metabolic syndrome. The molecule is a fat storage and energy source, and it impacts obesity. It impacts atherosclerosis, pancreatitis, cardiovascular disease, and thyroxine treatment. | CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCC(C)C | [
"Cancer",
"nutrient",
"inflammatory",
"Energy storage",
"Metabolic syndrome",
"Membrane stabilizer",
"Obesity",
"Fat storage",
"Energy source",
"Atherosclerosis",
"Pancreatitis",
"Cardiovascular disease",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts aging and barth syndrome. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts diabetic heart disease, non-alcoholic fatty liver disease, and tangier disease. | CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Aging",
"Cholesterol translocation",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts alzheimer's disease, diabetes mellitus type 2, parkinson's disease, and non-alcoholic fatty liver disease. | CCCCC/C=C\C/C=C\CC1OC1C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC | [
"Alzheimer's Disease",
"Diabetes mellitus type 2",
"Parkinson's disease",
"Non-alcoholic fatty liver disease",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, membrane stabilizer, and fat storage that has an effect on cancer and impacts both atherosclerosis and pancreatitis. The molecule is a inflammatory and energy storage, and it impacts cardiovascular disease. The molecule is a energy source and belongs to the thyroxine treatment class of molec... | CCC(C)CCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"Atherosclerosis",
"Cancer",
"nutrient",
"Pancreatitis",
"Membrane stabilizer",
"Fat storage",
"Cardiovascular disease",
"inflammatory",
"Energy storage",
"Metabolic syndrome",
"Thyroxine treatment",
"Energy source",
"Obesity"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fgfr inhibitor. | C=CC(=O)N1CCCC(c2cc(-c3cc4cc(C)cc(OC)c4s3)c(C(N)=NC=N)[nH]2)C1 | [
"fgfr inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a factor xia inhibitor. | NC(CCC(=O)N1CC=C(c2cccc3c2CCN(C(=O)C2CC(c4cccc(Cl)c4F)=NO2)C3C(=O)Nc2ccc(C(=O)O)cc2)CC1)C(=O)O | [
"factor xia inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts alzheimer's disease, non-alcoholic fatty liver disease, parkinson's disease, and diabetes mellitus type 2. | CCCCC/C=C\C=C/[C@@H](O)C/C=C\C/C=C/CCCC(=O)OC[C@H](COP(=O)(O)OCCN)O/C=C/CCCCCCCCCCCCCCCC | [
"Alzheimer's Disease",
"Non-alcoholic fatty liver disease",
"Parkinson's disease",
"nutrient",
"Diabetes mellitus type 2"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti viral and a hbv inhibitor, belonging to the hepatitis b treatment class of molecules. | CCOC(=O)c1cc2c(C(C)(F)F)cc(F)cc2[nH]1 | [
"hepatitis b treatment",
"anti viral",
"hbv inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts diabetic heart disease, tangier disease, and barth syndrome. The molecule is a apoptosis, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts aging and non-alcoholic fatty liver disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Barth syndrome",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Aging",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts diabetic heart disease, aging, and barth syndrome. The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Aging",
"Barth syndrome",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a cholesterol translocation that impacts tangier disease, barth syndrome, and aging. The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts diabetic heart disease and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Apoptosis",
"Tangier disease",
"Barth syndrome",
"Cholesterol translocation",
"Aging",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure that impacts barth syndrome, aging, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, cholesterol translocation that impacts tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Aging",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule has Mild ketone-like odor. Hazardous decomposition products formed under fire conditions - carbon oxides. Light may cause polymerization. The molecule is a waste product. | CC(=O)CC(C)=O | [
"Odor_evaluation",
"Decomposition_evaluation",
"Polymerization_evaluation",
"Waste product"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts tangier disease, barth syndrome, and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a thrombin inhibitor and a anti thrombotic. | Br.CN(c1cc(C(=O)Cn2c(=N)n(Cc3ccccc3)c3ccccc32)cc(C(C)(C)C)c1O)S(=O)(=O)Cc1ccccc1 | [
"thrombin inhibitor",
"anti thrombotic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a emulsifier that is woody and fresh. The molecule is a energy source and a nutrient, as well as hay and dry. The molecule is a membrane stabilizer that is green and resinous. The molecule is a energy storage, a flavoring agent, a surfactant, and pine. | CCC(C)[C@@H]1NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCS(C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCS(C)=O)NC1=O | [
"woody",
"Emulsifier",
"fresh",
"hay",
"dry",
"Energy source",
"nutrient",
"Membrane stabilizer",
"green",
"resinous",
"Energy storage",
"pine",
"Flavoring agent",
"surfactant"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti ulcer. | CSC(=C[N+](=O)[O-])NCCSCc1[nH]cnc1CO | [
"anti ulcer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, cholesterol translocation that impacts aging and tangier disease. The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts non-alcoholic fatty liver disease, barth syndrome, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Aging",
"Cholesterol translocation",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Apoptosis",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, apoptosis, cholesterol translocation that impacts barth syndrome and aging. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, tangier disease, and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCC(C)CC | [
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Aging",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a flavoring agent, a flavor, butter, butterscotch, and fruity. The molecule is a nutrient, a laboratory chemical, sharp, buttery, tart, and fruit. | O=C(/C=C/c1ccc(OC2OC(CO)C(O)C(O)C2OC2OCC(O)(CO)C2O)cc1)c1ccc(O)cc1O | [
"Flavoring agent",
"butter",
"flavor",
"butterscotch",
"fruity",
"nutrient",
"sharp",
"Laboratory chemical",
"buttery",
"tart",
"fruit"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | O=c1cc(-c2ccc(O)c(O)c2)oc2c(C3OCC(O)C(O)C3O)c(O)c(C3OC(CO)C(O)C(O)C3O)c(O)c12 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that affects breast cancer by impacting ulcerative colitis, cervical cancer, and atherosclerosis. | CC/C=C\C[C@@H](O)/C=C/C=C\C/C=C\C=C\[C@@H](O)/C=C\CCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCC/C=C\C/C=C\C/C=C\CCCCC | [
"Breast cancer",
"Ulcerative colitis",
"Cervical cancer",
"Atherosclerosis",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutritional supplement, a proton trap for oxidative phosphorylation, and a energy source, and it impacts aging. The molecule is a cholesterol translocation, apoptosis, energy storage that impacts barth syndrome and diabetic heart disease. The molecule is a membrane stabilizer and a emulsifier, it impa... | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCC/C=C\C=C/CCCCCC | [
"Nutritional supplement",
"Proton trap for oxidative phosphorylation",
"Aging",
"Energy source",
"Barth syndrome",
"Diabetic heart disease",
"Cholesterol translocation",
"Apoptosis",
"Energy storage",
"Membrane stabilizer",
"Tangier disease",
"Emulsifier",
"Smooth",
"surfactant",
"food a... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti atherosclerotic class of molecules. | CCCCCCCCCCCCCNc1ccc(CCCC(=O)O)cc1 | [
"anti atherosclerotic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation that impacts tangier disease, barth syndrome, aging, and diabetic heart disease. | CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C | [
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Barth syndrome",
"Aging",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer and a stabilizing cytochrome oxidase, impacting both barth syndrome and aging. The molecule is a surfactant, nutritional supplement, stabilizing mitochondrial structure, apoptosis, energy storage. The molecule is a food additive and a proton trap for oxidative phosphorylation, it i... | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C | [
"Barth syndrome",
"Membrane stabilizer",
"Aging",
"Stabilizing cytochrome oxidase",
"surfactant",
"Nutritional supplement",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Energy storage",
"Smooth",
"food additive",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Ener... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is alzheimer's treatment. | CSc1ccc(CC(=O)NC(Cc2cc(F)cc(F)c2)C(O)CNCCC2OCCO2)cc1 | [
"alzheimer's treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts aging, barth syndrome, and tangier disease. The molecule is a cholesterol translocation, apoptosis, proton trap for oxidative phosphorylation that impacts diabetic heart disease and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Aging",
"Barth syndrome",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
When heated to decomp ... emits toxic fumes of nitrogen oxides. | c1ccc2nc3ccccc3cc2c1 | [
"Decomposition_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCO)COP(=O)(O)OC[C@H](N)C(=O)O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and nutrient, and it impacts pancreatitis. It impacts cardiovascular disease, atherosclerosis, thyroxine treatment, and metabolic syndrome. | CCCCCCCC/C=C\CCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Fat storage",
"nutrient",
"Pancreatitis",
"Cardiovascular disease",
"Atherosclerosis",
"Thyroxine treatment",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, apoptosis, proton trap for oxidative phosphorylation that impacts aging and tangier disease. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, diabetic heart disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Cholesterol translocation",
"Aging",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
When heated to decomposition it burns or explodes. The molecule has Repulsive odor. | [SiH4] | [
"Decomposition_evaluation",
"Odor_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a dyslipidemia treatment that impacts hyperlipidemia treatment. | C=Cc1ccc(C2(O)CCN(C(=O)OC(C)(C)C)C2)cc1 | [
"hyperlipidemia treatment",
"dyslipidemia treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, membrane stabilizer, energy source, energy storage. | C#CC#CCc1ccccc1 | [
"nutrient",
"Membrane stabilizer",
"Energy source",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a thyroxine treatment that impacts both cardiovascular disease and atherosclerosis. The molecule is a fat storage and a nutrient, impacting both pancreatitis and metabolic syndrome. | CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Cardiovascular disease",
"Atherosclerosis",
"Thyroxine treatment",
"Pancreatitis",
"Metabolic syndrome",
"Fat storage",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a surfactant and a nutritional supplement, it impacts non-alcoholic fatty liver disease, and is smooth. The molecule is a stabilizing mitochondrial structure, energy storage, membrane stabilizer, energy source that impacts diabetic heart disease. The molecule is a proton trap for oxidative phosphorylati... | CCC(C)CCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C | [
"surfactant",
"Nutritional supplement",
"Non-alcoholic fatty liver disease",
"Smooth",
"Stabilizing mitochondrial structure",
"Energy storage",
"Membrane stabilizer",
"Diabetic heart disease",
"Energy source",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Stabilizing cytochr... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
In order to study the photoreactivity of pirimicarb (2-(dimethylamino)-5,6-dimethyl-pyrimidin-4-yl-n-dimethylcarbamate ) on plant surfaces, model experiments with organic solvents were performed. pirimicarb decomposed readily when irradiated (lambda > 280 nm) in the presence of the selected model solvents to form a num... | Cc1nc(N(C)C)nc(OC(=O)N(C)C)c1C | [
"Decomposition_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis that impacts barth syndrome and aging. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts tangier disease, non-alcoholic fatty liver disease, and diabetic heart disease. | CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C | [
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Apoptosis",
"Barth syndrome",
"Aging",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing mitochondrial structure, apoptosis that impacts barth syndrome and tangier disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, aging, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Tangier disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Aging",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is fruit, vanilla, and sweet; additionally, it is phenolic and metallic. The molecule is guaiacol, powdery, and flower; additionally, it is burnt and smoky. | C=C(C)[C@H]1CCC(=C)[C@H](OO)C1 | [
"fruit",
"vanilla",
"sweet",
"phenolic",
"metallic",
"guaiacol",
"powdery",
"flower",
"burnt",
"smoky"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer and is part of the thyroxine treatment class, affecting pancreatitis, cancer, obesity, and metabolic syndrome. The molecule is a inflammatory and fat storage, and it impacts cardiovascular disease. The molecule is a energy source, a nutrient, and a energy storage, and it impacts at... | CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC | [
"Membrane stabilizer",
"Pancreatitis",
"Cancer",
"Thyroxine treatment",
"Obesity",
"Metabolic syndrome",
"inflammatory",
"Fat storage",
"Cardiovascular disease",
"Atherosclerosis",
"Energy source",
"nutrient",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on breast cancer, and impacts parkinson's disease, seizure, and alzheimer's disease. It influences both colorectal cancer and stomach cancer, as well as affecting cardiovascular disease and diabetes mellitus. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCCCC(=O)OC[C@H](COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O)OC(=O)CCCCCCCC(O)/C=C/C=C/C/C=C/CC | [
"Parkinson's disease",
"Breast cancer",
"Seizure",
"Alzheimer's Disease",
"Colorectal cancer",
"Stomach cancer",
"Cardiovascular disease",
"Diabetes mellitus"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts cervical cancer, atherosclerosis, ulcerative colitis, and breast cancer. | CCCCCCCC/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC | [
"Cervical cancer",
"Atherosclerosis",
"Ulcerative colitis",
"Breast cancer",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts diabetic heart disease, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a apoptosis, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts tangier disease and aging. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts non-alcoholic fatty liver disease and barth syndrome. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts aging, diabetic heart disease, and tangier disease. | CCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Cholesterol translocation",
"Aging",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a diabetes treatment, a glycogen phosphorylase inhibitor, and hyperlipidemia treatment. | NC(=O)C(C(=O)NC1CCSc2ccccc21)c1ccccc1 | [
"diabetes treatment",
"glycogen phosphorylase inhibitor",
"hyperlipidemia treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that affects cervical cancer by impacting breast cancer, ulcerative colitis, and atherosclerosis. | CCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCC(O)C(O)C/C=C\C/C=C\C/C=C\CCCCC | [
"Cervical cancer",
"Breast cancer",
"nutrient",
"Ulcerative colitis",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory, a energy source, and a energy storage that impacts both pancreatitis and atherosclerosis, and is thyroxine treatment. The molecule is a fat storage and nutrient, and it impacts obesity. The molecule is a membrane stabilizer that impacts cardiovascular disease, metabolic syndrome, and can... | CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCC(C)C | [
"inflammatory",
"Thyroxine treatment",
"Energy source",
"Pancreatitis",
"Atherosclerosis",
"Energy storage",
"Obesity",
"Fat storage",
"nutrient",
"Cardiovascular disease",
"Membrane stabilizer",
"Metabolic syndrome",
"Cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis that impacts diabetic heart disease, barth syndrome, aging, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, cholesterol translocation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Apoptosis",
"Diabetic heart disease",
"Barth syndrome",
"Aging",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis, stabilizing mitochondrial structure that impacts aging. The molecule is a proton trap for oxidative phosphorylation that impacts tangier disease, diabetic heart disease, barth syndrome, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCC | [
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Aging",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Diabetic heart disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a member of the thyroxine treatment class and affects both atherosclerosis and metabolic syndrome. The molecule is a fat storage and a nutrient, impacting both cardiovascular disease and pancreatitis. | CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(=O)OC[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC | [
"Atherosclerosis",
"Metabolic syndrome",
"Thyroxine treatment",
"Cardiovascular disease",
"Fat storage",
"Pancreatitis",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti bacterial. | C=CCOC(=O)C(O)N1C(=O)C(C(C)O[Si](C)(C)C(C)(C)C)C1CC(=O)c1ccc2c(c1)N(C)C(=O)CO2 | [
"anti bacterial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts aging. The molecule is a cholesterol translocation that impacts diabetic heart disease, non-alcoholic fatty liver disease, barth syndrome, and tangier disease. | CCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCC(C)CC | [
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Barth syndrome",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts aging, barth syndrome, and tangier disease. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, cholesterol translocation that impacts non-alcoholic fatty liver disease and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Aging",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Apoptosis",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is organic light-emitting. | c1ccc2c(c1)ccc1c2c2cc3c(c4ccccc4n3-c3nc(-n4c5ccccc5c5ccccc54)c4sc5ccccc5c4n3)c3c4ccccc4n1c23 | [
"organic light-emitting"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti bacterial class of molecules. | CCn1cc(C(=O)O)c(=O)c2cnc(N3CC4CC=CC(NC)C4C3)c(Cl)c21 | [
"anti bacterial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a sglt2 inhibitor and belongs to the cancer treatment class of molecules. | Cc1cc(Cl)ccc1S(=O)(=O)Nc1cc(Cl)c(Oc2cnc3ccccc3c2)c(Cl)c1 | [
"cancer treatment",
"sglt2 inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts seizure, stomach cancer, diabetes mellitus, and colorectal cancer. It has an effect on breast cancer, and impacts alzheimer's disease, cardiovascular disease, and parkinson's disease. | CCCCC/C=C\C/C=C\CC1OC1C/C=C\CCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC)COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O | [
"Seizure",
"Stomach cancer",
"Diabetes mellitus",
"Colorectal cancer",
"Alzheimer's Disease",
"Cardiovascular disease",
"Breast cancer",
"Parkinson's disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCCCC(=O)O[C@H]1C[C@@]2(COC(C)=O)[C@@H](C=C1C)O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@]12CO2 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, tangier disease, and diabetic heart disease. The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts barth syndrome and aging. | CCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Diabetic heart disease",
"Barth syndrome",
"Cholesterol translocation",
"Aging",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, proton trap for oxidative phosphorylation that impacts aging and barth syndrome. The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts tangier disease, diabetic heart disease, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C | [
"Stabilizing mitochondrial structure",
"Aging",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, inflammatory, thyroxine treatment, fat storage that impacts pancreatitis and obesity. The molecule is a energy source that affects cancer by impacting metabolic syndrome. The molecule is a membrane stabilizer and a energy storage, impacting both cardiovascular disease and atherosclerosis. | CCC(C)CCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C | [
"nutrient",
"Pancreatitis",
"Obesity",
"inflammatory",
"Thyroxine treatment",
"Fat storage",
"Cancer",
"Metabolic syndrome",
"Energy source",
"Cardiovascular disease",
"Membrane stabilizer",
"Energy storage",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a pak inhibitor and a cancer treatment. | CN(c1ccc(Nc2ncc3cc(C#Cc4nccn4C)c(=O)n(Cc4ccnn4CC(F)(F)F)c3n2)cc1)C1CCCNC1 | [
"pak inhibitor",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a tyrosine kinase inhibitor and is cancer treatment. | COC(=O)Nc1ccc(-c2cnc3cnc(CN(C)c4ccc(C#N)cc4)cn23)cc1 | [
"cancer treatment",
"tyrosine kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, apoptosis, cholesterol translocation that impacts barth syndrome and diabetic heart disease. The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, aging, and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Apoptosis",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Aging",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts aging, non-alcoholic fatty liver disease, and tangier disease. The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, cholesterol translocation that impacts diabetic heart disease and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Aging",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Diabetic heart disease",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hcv protease inhibitor and anti viral, and it impacts hepatitis c treatment. | CN(C1CC1)S(=O)(=O)CC1(N=C=O)CCCCC1 | [
"anti viral",
"hepatitis c treatment",
"hcv protease inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is optoelectronic. | COCc1ccc(B(O)O)cc1F | [
"optoelectronic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a waste product and a anti tumor that impacts agitation, psychosis, and uremia. The molecule is a human metabolite, anti oxidant, fundamental metabolite that impacts cardiovascular disease and kidney disease. The molecule is a anti biotic and belongs to the pesticide class of molecules, with effects on ... | N[C@@H](CS)C(=O)O | [
"Waste product",
"Agitation",
"Psychosis",
"Uremia",
"anti tumor",
"Cardiovascular disease",
"human metabolite",
"anti oxidant",
"Kidney disease",
"fundamental metabolite",
"cancer preventive",
"anti biotic",
"Dementia",
"Nausea",
"pesticide",
"Stroke",
"Peripheral neuropathy",
"Ch... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation that impacts barth syndrome, diabetic heart disease, aging, and tangier disease. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCC | [
"Barth syndrome",
"Diabetic heart disease",
"Aging",
"Tangier disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts barth syndrome, diabetic heart disease, and aging. The molecule is a apoptosis, cholesterol translocation, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and tangier disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCC(C)CC | [
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Cholesterol translocation",
"Tangier disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts barth syndrome, tangier disease, and aging. | CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Apoptosis",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a dgat inhibitor and is metabolic disease treatment. | Cc1ccc2c(c1)c(C=CC(=O)N(NC(=O)c1cccc(F)c1)C(C)C)cn2C(=O)OC(C)(C)C | [
"metabolic disease treatment",
"dgat inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts barth syndrome, diabetic heart disease, and tangier disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts non-alcoholic fatty liver disease and aging. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)C | [
"Barth syndrome",
"Diabetic heart disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts aging and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation and a apoptosis that impacts tangier disease, barth syndrome, and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC | [
"Stabilizing mitochondrial structure",
"Aging",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Barth syndrome",
"Cholesterol translocation",
"Apoptosis",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis that impacts tangier disease, non-alcoholic fatty liver disease, aging, and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts barth syndrome. | CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCC(C)C | [
"Tangier disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Aging",
"Diabetic heart disease",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, a membrane stabilizer, and fruity. The molecule is a nutrient, surfactant, emulsifier, energy source. | CC(C)COc1cnccn1 | [
"Energy storage",
"fruity",
"Membrane stabilizer",
"nutrient",
"surfactant",
"Emulsifier",
"Energy source"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a mycotoxin and a metabolite. | COc1cc2c(cc1O)C1Cc3ccc(OC)c(OC)c3CN1CC2 | [
"mycotoxin",
"metabolite"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a lipoxygenase inhibitor, which is both anti caries and anti mutagenic, as well as anti amebic, and it belongs to the pesticide and pharmaceutical classes of molecules. The molecule is a anti inflammatory and a neuroprotective agent, belonging to the anti carcinogenic class of molecules. The molecule is... | CCOc1cc(COC)ccc1O | [
"lipoxygenase inhibitor",
"anti caries",
"anti mutagenic",
"anti amebic",
"pesticide",
"Pharmaceutical",
"anti inflammatory",
"anti carcinogenic",
"neuroprotective agent",
"anti tumor",
"anti radicular",
"nutrient",
"anti cancer agent",
"anti streptococcic",
"anti oxidant",
"bitter",
... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a member of the muscarinic receptor antagonist class and affects copd treatment. | COc1ccc(C(Cc2c(Cl)c[n+]([O-])cc2Cl)OC(=O)c2cccc(S(=O)(=O)NC(C(=O)OC3CN4CCC3CC4)c3ccccc3)c2)cc1OC | [
"COPD treatment",
"muscarinic receptor antagonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a viral replication inhibitor, a hcv inhibitor, and hcv treatment. | O=C1NC(c2cccc(F)c2)Nc2nc(Cl)ccc21 | [
"viral replication inhibitor",
"hcv inhibitor",
"hcv treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is sweet, floral, and chocolate. The molecule is a nutrient and a flavoring agent, as well as honey and amber. | C=C(C)C(O)Cc1c(O)cc(OC)c(C(=O)/C=C/c2ccc(O)cc2)c1O | [
"sweet",
"floral",
"chocolate",
"honey",
"nutrient",
"Flavoring agent",
"amber"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a food additive, a surfactant, and a energy storage, and it impacts aging. The molecule is a membrane stabilizer, cholesterol translocation, stabilizing mitochondrial structure that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a energy source, stabilizing cytochr... | CCC(C)CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"food additive",
"surfactant",
"Energy storage",
"Aging",
"Membrane stabilizer",
"Cholesterol translocation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Energy source",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phos... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both cardiovascular disease and atherosclerosis. The molecule is a nutrient and a thyroxine treatment, impacting both metabolic syndrome and pancreatitis. | CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC | [
"Cardiovascular disease",
"Atherosclerosis",
"Fat storage",
"nutrient",
"Thyroxine treatment",
"Metabolic syndrome",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts parkinson's disease, alzheimer's disease, non-alcoholic fatty liver disease, and diabetes mellitus type 2. | CCCCC/C=C\C/C=C\CCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCC[C@H]1[C@@H](O)CC(=O)[C@@H]1/C=C/[C@@H](O)CCCCC)COP(=O)(O)OCCN | [
"Parkinson's disease",
"nutrient",
"Alzheimer's Disease",
"Non-alcoholic fatty liver disease",
"Diabetes mellitus type 2"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a high luminous efficiency, organic electroluminescent compound, and electroluminescent compound. | C1=CCC(c2cc3ccccc3cc2-c2ccc3sc4ccc(C5C=c6ccccc6=C6C=CCCC65)cc4c3c2)C=C1 | [
"high luminous efficiency",
"organic electroluminescent compound",
"electroluminescent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.